The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis

Overview of attention for article published in PLOS ONE, October 2012

Altmetric Badge

Mentioned by

news: 27 news outlets
policy: 1 policy source

f1000: 1 research highlight platform

Citations

dimensions_citation: 180 Dimensions

Readers on

mendeley: 145 Mendeley

Summary News Policy documents Research highlights Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer : Final appraisal determination committee papers

Cited by National Institute for Health and Care Excellence on 12 Nov 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 21 Aug 2020

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.